BCM

Be Biopharma Announces FDA Clearance of IND Application for BE-101 in Hemophilia B

Retrieved on: 
火曜日, 5月 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Genetics, Clinical Trials, Phenotype, Plasma, University, FIX, Investigational New Drug, Food, Factor IX, IND, BCMS, Disease, Safety, BCM, Medical director, Haemophilia, Chronic pain, Engineering, Pharmaceutical industry

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), today announced the clearance of its Investigational New Drug application (IND) from the U.S. Food and Drug Administration (FDA) for BE-101, a first-in-class BCM in development for the potential treatment of hemophilia B.

Key Points: 
  • Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), today announced the clearance of its Investigational New Drug application (IND) from the U.S. Food and Drug Administration (FDA) for BE-101, a first-in-class BCM in development for the potential treatment of hemophilia B.
  • The Phase 1/2 clinical trial, BeCoMe-9, is a multi-center, first-in-human dose escalation study designed to assess the safety and preliminary efficacy of BE-101 in adult participants with moderately severe to severe hemophilia B.
  • Adults and children with hemophilia B have long sought a single dose Factor IX replacement therapy with extreme durability while retaining the dosing flexibility of the current standard of care.
  • Additionally, the redosability of BE-101 has been demonstrated, resulting in a predictable increase in plasma FIX levels.

ComEd Completes One of Nation’s First Neighborhood Scale Community Microgrids in Bronzeville on Chicago’s South Side

Retrieved on: 
金曜日, 5月 24, 2024
Utilities, Energy, Chicago Police Department, EV, De La Salle Institute, Restaurant, Mentorship, Mathematics, Commonwealth Edison, IIT, News, Argonne National Laboratory, DOE, LED, Commonwealth, Illinois Institute of Technology, EXC, Computer, Rain, Engineering, Weather, BCM, CHA, Exelon, 38th Street, 33rd Street, Student, Electricity, Electrical engineering, Software, State Street, Primary energy, Quality of life, City, Renewable energy

ComEd today joined leaders from the U.S. Department of Energy (DOE), the City of Chicago and the community of Bronzeville to mark the completion of the Bronzeville Community Microgrid (BCM) – one of the nation’s first neighborhood scale community microgrids.

Key Points: 
  • ComEd today joined leaders from the U.S. Department of Energy (DOE), the City of Chicago and the community of Bronzeville to mark the completion of the Bronzeville Community Microgrid (BCM) – one of the nation’s first neighborhood scale community microgrids.
  • “This project is the culmination of nearly a decade of work with the Department of Energy, ComEd, and Bronzeville investing to make this a reality,” U.S.
  • Bronzeville was selected following a comprehensive study to evaluate locations where a microgrid could be located.
  • For more information visit ComEd.com , and connect with the company on Facebook , Instagram , LinkedIn , X , and YouTube .

Endava Announces Third Quarter Fiscal Year 2024 Results

Retrieved on: 
木曜日, 5月 23, 2024
Professional Services, Data Management, Technology, Data Analytics, Software, Consulting, TMT, Overalls, Conference, Capital market, EPS, Growth, FINANCIAL, BCM, METRICS, Acquisition, United States dollar, Environment, Nature, DAVA, Cryptocurrency

Endava plc (NYSE: DAVA) ("Endava" or the "Company"), a leading technology services company combining world-class engineering, industry expertise and a people-centric mindset, today announced results for the three months ended March 31, 2024, the third quarter of its 2024 fiscal year ("Q3 FY2024").

Key Points: 
  • Endava plc (NYSE: DAVA) ("Endava" or the "Company"), a leading technology services company combining world-class engineering, industry expertise and a people-centric mindset, today announced results for the three months ended March 31, 2024, the third quarter of its 2024 fiscal year ("Q3 FY2024").
  • THIRD QUARTER FISCAL YEAR 2024 FINANCIAL HIGHLIGHTS:
    Revenue for Q3 FY2024 was £174.4 million, a decrease of 14.3% compared to £203.5 million in the same period in the prior year.
  • At March 31, 2024, Endava had cash and cash equivalents of £190.0 million, compared to £164.7 million at June 30, 2023.
  • This above guidance for the fourth quarter and full fiscal year 2024 assumes the exchange rates on April 30, 2024 (when the exchange rate was 1 British Pound to 1.25 US Dollar and 1.17 Euro).

Be Biopharma Expands Scientific Advisory Board with the Appointment of Cell and Gene Therapy Leader Dr. Paula Cannon

Retrieved on: 
火曜日, 5月 21, 2024
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, Medicine, Cell, Immunology, HIV, Orthornavirae, University, BCMS, Engineering, BCM, Gene, Molecular biology, Vaccination, RNA, Society, Therapy, Haemophilia, Virus, Infection, Gene editing, Vaccine

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), today announced the addition of Paula Cannon, Ph.D., to its Scientific Advisory Board.

Key Points: 
  • Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), today announced the addition of Paula Cannon, Ph.D., to its Scientific Advisory Board.
  • Dr. Cannon, Distinguished Professor of Molecular Microbiology and Immunology at the Keck School of Medicine of the University of Southern California, was recently appointed President of the American Society for Gene and Cell Therapy (ASGCT).
  • Dr. Cannon will work with other members of the Scientific Advisory Board to provide scientific and clinical guidance as the Company advances its pipeline of B Cell Medicine (BCM) programs, including its lead program, BE-101, a first-in-class BCM for the treatment of hemophilia B.
  • She is joined on the Scientific Advisory Board by experts in the fields of B cell biology, cell and gene therapy, genetic and infectious disease, and oncology.

JMR Services® and A-Plus P&A Close Previously-Announced Merger and Acquire BCM & Associates, Creating the Leading Pure-Play P&A Service Provider in the Nation

Retrieved on: 
水曜日, 5月 15, 2024
Energy, Professional Services, Business, Oil, Gas, Permian, Methane, CFO, Growth, BCM, Acquisition, Multimedia, JMR, Record, Management

JMR Services (“JMR”) today announced the closing of its previously-announced merger with A-Plus P&A LLC (“A-Plus”) and subsequently acquired BCM & Associates, Inc. (“BCM”), resulting in the largest pure-play, full-service plug and abandonment (“P&A”) service provider in the nation.

Key Points: 
  • JMR Services (“JMR”) today announced the closing of its previously-announced merger with A-Plus P&A LLC (“A-Plus”) and subsequently acquired BCM & Associates, Inc. (“BCM”), resulting in the largest pure-play, full-service plug and abandonment (“P&A”) service provider in the nation.
  • With yards in Midland, Texas, and Hobbs, New Mexico, the acquisition continues expanding upon JMR’s leading footprint in the Permian, Denver-Julesburg, and San Juan Basins.
  • “It marks a pivotal moment in the P&A sector, as customers increasingly value established, safety-focused contractors that ensure improved service and operational efficiency.
  • With a strong balance sheet and minimal leverage, we're poised to expand JMR's service line into new basins, driving our growth initiative forward.

Be Biopharma Announces New Preclinical Data for Novel B Cell Medicine for the Potential Treatment of Hypophosphatasia

Retrieved on: 
金曜日, 5月 10, 2024
Biotechnology, Technology, Managed Care, Health, Pharmaceutical, Health Technology, Research, Artificial Intelligence, Genetics, Science, Clinical Trials, Patient, Cas9, Cell, ALPL, Gene expression, Protein, AAV, BCMS, HDR, Disease, HPP, MC3T3, BCM, Gene, CCR5, Injection, Enzyme replacement therapy, Society, CRISPR, DSM-IV codes, ALP, Engineering, Vaccine

Researchers used CRISPR/Cas9 precision gene engineering and artificial intelligence-guided protein design to modify primary human B cells to produce ALP, an enzyme deficient in people living with HPP.

Key Points: 
  • Researchers used CRISPR/Cas9 precision gene engineering and artificial intelligence-guided protein design to modify primary human B cells to produce ALP, an enzyme deficient in people living with HPP.
  • The findings were presented during a poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting on Friday, May 10, at 12:00pm ET.
  • HPP is a rare genetic disease caused by loss of function mutations in the ALPL gene which leads to deficient ALP activity.
  • Robust in vitro phenotypic correction using ALP secreting BCMs (ALP-BCMs) was demonstrated in the MC3T3 osteoblast precursor mineralization model.

NEO Semiconductor Reveals a Performance Boosting Floating Body Cell Mechanism for 3D X-DRAM during IEEE IMW 2024 in Seoul, Republic of Korea

Retrieved on: 
月曜日, 5月 13, 2024
3D, NEO, IMW, TCAD, SAN, DRAM, BCM, Modulation, Technology CAD, Memory, Computer data storage

SAN JOSE, Calif., May 13, 2024 /PRNewswire/ -- NEO Semiconductor, a leading developer of innovative technologies for 3D NAND flash and DRAM memory, today announced a performance boosting Floating Body Cell Mechanism for 3D X-DRAM. Andy Hsu, Founder & CEO presented groundbreaking Technology CAD (TCAD) simulation results for NEO's 3D X-DRAM™ during the 16th IEEE International Memory Workshop (IMW) 2024 in Seoul, Republic of Korea.

Key Points: 
  • SAN JOSE, Calif., May 13, 2024 /PRNewswire/ -- NEO Semiconductor , a leading developer of innovative technologies for 3D NAND flash and DRAM memory, today announced a performance boosting Floating Body Cell Mechanism for 3D X-DRAM.
  • Neo Semiconductor reveals a unique performance boosting mechanism called Back-gate Channel-depth Modulation (BCM) for Floating Body Cell that can increase data retention by 40,000X and sensing window by 20X.
  • "Unlike the traditional 2D Floating Body Cell that uses body effect to change the cell current, our BCM mechanism employs a back-gate voltage to modulate the channel depth.
  • NEO Semiconductor's 3D X-DRAM™ is a first-of-its-kind 3D NAND-like DRAM cell array structure based on floating body cell technology.

Bluerock Capital Markets Hires Jeffrey Klepacki as Executive Vice President and National Sales Manager

Retrieved on: 
月曜日, 5月 13, 2024
Allianz Global Investors, Rutgers University, Bachelor, World championship, Growth, BCM, Capital, Delaware Investments, Vontobel, DST, Olympic Games, Real estate investment trust, FINRA, Atlanta

NEW YORK, May 13, 2024 /PRNewswire/ -- Bluerock Capital Markets ("BCM"), a leading distributor of institutional alternative investment products and the dedicated dealer manager for Bluerock, announced today that it has hired industry veteran Jeffrey Klepacki to serve as Executive Vice President and National Sales Manager.

Key Points: 
  • NEW YORK, May 13, 2024 /PRNewswire/ -- Bluerock Capital Markets ("BCM"), a leading distributor of institutional alternative investment products and the dedicated dealer manager for Bluerock, announced today that it has hired industry veteran Jeffrey Klepacki to serve as Executive Vice President and National Sales Manager.
  • Mr. Klepacki will further directly oversee the growth of Bluerock offered investment programs with key 3rd party distribution partner platforms.
  • Mr. Klepacki brings more than 23 years of securities industry experience and 16 years of sales management experience to his role at Bluerock.
  • In his new executive role, Mr. Klepacki will report directly to BCM's CEO Jeffrey Schwaber.

The Jackson Laboratory appoints Mary Dickinson as chief scientific officer

Retrieved on: 
金曜日, 5月 10, 2024
Genomics, Cardiovascular disease, Faculty, Baylor College of Medicine, KOMP, Jackson Laboratory, University, International Society, Disease, Health, Mouse, Society, Alzheimer's disease, Research, Growth, Cancer, JAX, BCM, American Institute, ZZZ3, Immersion, Biological engineering, Genetics, Columbia University, University of California, Davis, History, California Institute of Technology, NIH, Medicine, Senate, Vanderbilt University, Management

BAR HARBOR, Maine, May 10, 2024 /PRNewswire/ -- Mary Dickinson, Ph.D., an internationally recognized geneticist, developmental biologist and bioengineer who has pioneered the understanding of human disease through advanced imaging technology, has joined The Jackson Laboratory (JAX) as the inaugural executive vice president and chief scientific officer. Dickinson will lead JAX's research enterprise, overseeing scientific strategy and operations to build on JAX's unique strengths in genetics and genomics.

Key Points: 
  • Dickinson will lead JAX's research enterprise, overseeing scientific strategy and operations to build on JAX's unique strengths in genetics and genomics.
  • "With this critical appointment of our chief scientific officer, our team is well-poised to lead major advances on our strategic plan and research priorities in 2024 and beyond."
  • "JAX has long been known as a world leader in research innovation, genetic mechanisms and models for disease," said Dickinson.
  • "JAX wants to help people make a difference for as many people as possible, from those in rural Maine to Tokyo," said Dickinson.

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Retrieved on: 
木曜日, 5月 9, 2024
FDA, Investment, Risk, Destiny, IND, Autoimmune disease, Enrollment, Death, Hospital, GAAP, NK, GEJ, Multiple myeloma, CRS, HER2, Pharmacokinetics, Graft-versus-host disease, Food, Lupus, Data, ADR, BCL, Histology, Therapy, BCMA, Autoimmunity, Safety, Trastuzumab, Research, TRAC, Incidence, IPSC, Chronic lymphocytic leukemia, Acute leukemia, Investigational New Drug, Cancer, Cell, Cmax, Patient, Gene, Society, B-cell lymphoma, BCM, Cytokine release syndrome, Immune system, SLE, Vaccine

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today reported business highlights and financial results for the first quarter ended March 31, 2024.

Key Points: 
  • The patient was discharged after a three-day hospital stay without any notable adverse events.
  • The Company will conduct a conference call today, Thursday, May 9, 2024 at 5:00 p.m.
  • ET to review financial and operating results for the quarter and full year ended March 31, 2024.
  • The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com.